Literature DB >> 33874732

Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy.

Rahul Goli1, Jian Li1, Jeff Brandimarto1, Lisa D Levine2, Valerie Riis2, Quentin McAfee1, Steven DePalma3,4, Alireza Haghighi3,4, J G Seidman3, Christine E Seidman3,4, Daniel Jacoby5, George Macones6, Daniel P Judge7, Sarosh Rana8, Kenneth B Margulies1, Thomas P Cappola1, Rami Alharethi9, Julie Damp10, Eileen Hsich11, Uri Elkayam12, Richard Sheppard13, Jeffrey D Alexis14, John Boehmer15, Chizuko Kamiya16, Finn Gustafsson17,18, Peter Damm19,18, Anne S Ersbøll19,18, Sorel Goland20, Denise Hilfiker-Kleiner21, Dennis M McNamara22, Zolt Arany1.   

Abstract

BACKGROUND: Peripartum cardiomyopathy (PPCM) occurs in ≈1:2000 deliveries in the United States and worldwide. The genetic underpinnings of PPCM remain poorly defined. Approximately 10% of women with PPCM harbor truncating variants in TTN (TTNtvs). Whether mutations in other genes can predispose to PPCM is not known. It is also not known if the presence of TTNtvs predicts clinical presentation or outcomes. Nor is it known if the prevalence of TTNtvs differs in women with PPCM and preeclampsia, the strongest risk factor for PPCM.
METHODS: Women with PPCM were retrospectively identified from several US and international academic centers, and clinical information and DNA samples were acquired. Next-generation sequencing was performed on 67 genes, including TTN, and evaluated for burden of truncating and missense variants. The impact of TTNtvs on the severity of clinical presentation, and on clinical outcomes, was evaluated.
RESULTS: Four hundred sixty-nine women met inclusion criteria. Of the women with PPCM, 10.4% bore TTNtvs (odds ratio=9.4 compared with 1.2% in the reference population; Bonferroni-corrected P [P*]=1.2×10-46). We additionally identified overrepresentation of truncating variants in FLNC (odds ratio=24.8, P*=7.0×10-8), DSP (odds ratio=14.9, P*=1.0×10-8), and BAG3 (odds ratio=53.1, P*=0.02), genes not previously associated with PPCM. This profile is highly similar to that found in nonischemic dilated cardiomyopathy. Women with TTNtvs had lower left ventricular ejection fraction on presentation than did women without TTNtvs (23.5% versus 29%, P=2.5×10-4), but did not differ significantly in timing of presentation after delivery, in prevalence of preeclampsia, or in rates of clinical recovery.
CONCLUSIONS: This study provides the first extensive genetic and phenotypic landscape of PPCM and demonstrates that predisposition to heart failure is an important risk factor for PPCM. The work reveals a degree of genetic similarity between PPCM and dilated cardiomyopathy, suggesting that gene-specific therapeutic approaches being developed for dilated cardiomyopathy may also apply to PPCM, and that approaches to genetic testing in PPCM should mirror those taken in dilated cardiomyopathy. Last, the clarification of genotype/phenotype associations has important implications for genetic counseling.

Entities:  

Keywords:  cardiomyopathies; peripartum period

Mesh:

Year:  2021        PMID: 33874732      PMCID: PMC8113098          DOI: 10.1161/CIRCULATIONAHA.120.052395

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

1.  HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).

Authors:  Michael J Ackerman; Silvia G Priori; Stephan Willems; Charles Berul; Ramon Brugada; Hugh Calkins; A John Camm; Patrick T Ellinor; Michael Gollob; Robert Hamilton; Ray E Hershberger; Daniel P Judge; Hervè Le Marec; William J McKenna; Eric Schulze-Bahr; Chris Semsarian; Jeffrey A Towbin; Hugh Watkins; Arthur Wilde; Christian Wolpert; Douglas P Zipes
Journal:  Heart Rhythm       Date:  2011-08       Impact factor: 6.343

Review 2.  Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies.

Authors:  Raquel Yotti; Christine E Seidman; Jonathan G Seidman
Journal:  Annu Rev Genomics Hum Genet       Date:  2019-04-12       Impact factor: 8.929

3.  Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating Variants.

Authors:  Christopher M Haggerty; Scott M Damrauer; Michael G Levin; David Birtwell; David J Carey; Alicia M Golden; Dustin N Hartzel; Yirui Hu; Renae Judy; Melissa A Kelly; Rachel L Kember; H Lester Kirchner; Joseph B Leader; Lusha Liang; Chris McDermott-Roe; Apoorva Babu; Michael Morley; Zachariah Nealy; Thomas N Person; Arichanah Pulenthiran; Aeron Small; Diane T Smelser; Richard C Stahl; Amy C Sturm; Heather Williams; Aris Baras; Kenneth B Margulies; Thomas P Cappola; Frederick E Dewey; Anurag Verma; Xinyuang Zhang; Adolfo Correa; Michael E Hall; James G Wilson; Marylyn D Ritchie; Daniel J Rader; Michael F Murray; Brandon K Fornwalt; Zoltan Arany
Journal:  Circulation       Date:  2019-06-20       Impact factor: 29.690

4.  FLNC pathogenic variants in patients with cardiomyopathies: Prevalence and genotype-phenotype correlations.

Authors:  Flavie Ader; Pascal De Groote; Patricia Réant; Caroline Rooryck-Thambo; Delphine Dupin-Deguine; Caroline Rambaud; Diala Khraiche; Claire Perret; Jean François Pruny; Michèle Mathieu-Dramard; Marion Gérard; Yann Troadec; Laurent Gouya; Xavier Jeunemaitre; Lionel Van Maldergem; Albert Hagège; Eric Villard; Philippe Charron; Pascale Richard
Journal:  Clin Genet       Date:  2019-07-18       Impact factor: 4.438

5.  Truncating mutations on myofibrillar myopathies causing genes as prevalent molecular explanations on patients with dilated cardiomyopathy.

Authors:  A Janin; K N'Guyen; G Habib; C Dauphin; V Chanavat; P Bouvagnet; R Eschalier; N Streichenberger; P Chevalier; G Millat
Journal:  Clin Genet       Date:  2017-05-18       Impact factor: 4.438

Review 6.  Peripartum Cardiomyopathy.

Authors:  Zolt Arany; Uri Elkayam
Journal:  Circulation       Date:  2016-04-05       Impact factor: 29.690

7.  2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary.

Authors:  Jeffrey A Towbin; William J McKenna; Dominic J Abrams; Michael J Ackerman; Hugh Calkins; Francisco C C Darrieux; James P Daubert; Christian de Chillou; Eugene C DePasquale; Milind Y Desai; N A Mark Estes; Wei Hua; Julia H Indik; Jodie Ingles; Cynthia A James; Roy M John; Daniel P Judge; Roberto Keegan; Andrew D Krahn; Mark S Link; Frank I Marcus; Christopher J McLeod; Luisa Mestroni; Silvia G Priori; Jeffrey E Saffitz; Shubhayan Sanatani; Wataru Shimizu; J Peter van Tintelen; Arthur A M Wilde; Wojciech Zareba
Journal:  Heart Rhythm       Date:  2019-11       Impact factor: 6.343

8.  Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Eric D Smith; Neal K Lakdawala; Nikolaos Papoutsidakis; Gregory Aubert; Andrea Mazzanti; Anthony C McCanta; Prachi P Agarwal; Patricia Arscott; Lisa M Dellefave-Castillo; Esther E Vorovich; Kavitha Nutakki; Lisa D Wilsbacher; Silvia G Priori; Daniel L Jacoby; Elizabeth M McNally; Adam S Helms
Journal:  Circulation       Date:  2020-05-06       Impact factor: 29.690

9.  Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease.

Authors:  Angharad M Roberts; James S Ware; Daniel S Herman; Sebastian Schafer; John Baksi; Alexander G Bick; Rachel J Buchan; Roddy Walsh; Shibu John; Samuel Wilkinson; Francesco Mazzarotto; Leanne E Felkin; Sungsam Gong; Jacqueline A L MacArthur; Fiona Cunningham; Jason Flannick; Stacey B Gabriel; David M Altshuler; Peter S Macdonald; Matthias Heinig; Anne M Keogh; Christopher S Hayward; Nicholas R Banner; Dudley J Pennell; Declan P O'Regan; Tan Ru San; Antonio de Marvao; Timothy J W Dawes; Ankur Gulati; Emma J Birks; Magdi H Yacoub; Michael Radke; Michael Gotthardt; James G Wilson; Christopher J O'Donnell; Sanjay K Prasad; Paul J R Barton; Diane Fatkin; Norbert Hubner; Jonathan G Seidman; Christine E Seidman; Stuart A Cook
Journal:  Sci Transl Med       Date:  2015-01-14       Impact factor: 17.956

10.  Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Ray E Hershberger; Michael M Givertz; Carolyn Y Ho; Daniel P Judge; Paul F Kantor; Kim L McBride; Ana Morales; Matthew R G Taylor; Matteo Vatta; Stephanie M Ware
Journal:  Genet Med       Date:  2018-06-14       Impact factor: 8.822

View more
  15 in total

1.  It Is Time to Offer Genetic Testing to Women With Peripartum Cardiomyopathy.

Authors:  Zoltan Arany
Journal:  Circulation       Date:  2022-07-05       Impact factor: 39.918

Review 2.  Titin-related Cardiomyopathy: Is it a Distinct Disease?

Authors:  Celine F Santiago; Inken G Huttner; Diane Fatkin
Journal:  Curr Cardiol Rep       Date:  2022-06-27       Impact factor: 3.955

Review 3.  Emerging Genotype-Phenotype Associations in Dilated Cardiomyopathy.

Authors:  Joyce N Njoroge; Jennifer C Mangena; Chiaka Aribeana; Victoria N Parikh
Journal:  Curr Cardiol Rep       Date:  2022-07-28       Impact factor: 3.955

Review 4.  Animal Models of Cardiovascular Complications of Pregnancy.

Authors:  Zolt Arany; Denise Hilfiker-Kleiner; S Ananth Karumanchi
Journal:  Circ Res       Date:  2022-06-09       Impact factor: 23.213

Review 5.  Arrhythmias as Presentation of Genetic Cardiomyopathy.

Authors:  J Lukas Laws; Megan C Lancaster; M Ben Shoemaker; William G Stevenson; Rebecca R Hung; Quinn Wells; D Marshall Brinkley; Sean Hughes; Katherine Anderson; Dan Roden; Lynne W Stevenson
Journal:  Circ Res       Date:  2022-05-26       Impact factor: 23.213

Review 6.  A bibliometric review of peripartum cardiomyopathy compared to other cardiomyopathies using artificial intelligence and machine learning.

Authors:  M Grosser; H Lin; M Wu; Y Zhang; S Tipper; D Venter; J Lu; C G Dos Remedios
Journal:  Biophys Rev       Date:  2022-02-09

Review 7.  Pathophysiology and risk factors of peripartum cardiomyopathy.

Authors:  Martijn F Hoes; Zoltan Arany; Johann Bauersachs; Denise Hilfiker-Kleiner; Mark C Petrie; Karen Sliwa; Peter van der Meer
Journal:  Nat Rev Cardiol       Date:  2022-01-11       Impact factor: 49.421

Review 8.  Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies.

Authors:  Roddy Walsh; Joost A Offerhaus; Rafik Tadros; Connie R Bezzina
Journal:  Nat Rev Cardiol       Date:  2021-09-15       Impact factor: 32.419

Review 9.  Translation of New and Emerging Therapies for Genetic Cardiomyopathies.

Authors:  Adam S Helms; Andrea D Thompson; Sharlene M Day
Journal:  JACC Basic Transl Sci       Date:  2021-12-01

Review 10.  Peripartum cardiomyopathy: a global effort to find the cause and cure for the rare and little understood disease.

Authors:  Amy Li; K Campbell; S Lal; Y Ge; A Keogh; P S Macdonald; P Lau; John Lai; W A Linke; J Van der Velden; A Field; B Martinac; M Grosser; Cristobal Dos Remedios
Journal:  Biophys Rev       Date:  2022-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.